Pharmacovigilance and the process of Pharmacovigilance (New Drug Discovery and Development Part 6)

Pharmacovigilance and the process of Pharmacovigilance (New Drug Discovery and Development Part 6) by Dr. Shikha Parmar
Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. WHO established its Programme for International Drug Monitoring in response to the thalidomide disaster detected in 1961. (Credit- WHO Website)
The etymological roots for the word "pharmacovigilance" are pharmakon (Greek for drug) and vigilance (Latin for to keep watch). As such, pharmacovigilance heavily focuses on adverse drug reactions, or ADRs, which are defined as any response to a drug which is noxious and unintended, including lack of efficacy (the condition that this definition only applies with the doses normally used for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological disorder function was excluded with the latest amendment of the applicable legislation) Information received from patients and healthcare providers via pharmacovigilance agreements (PVAs), as well as other sources such as the medical literature, plays a critical role in providing the data necessary for pharmacovigilance to take place. In fact, in order to market or to test a pharmaceutical product in most countries, adverse event data received by the license holder (usually a pharmaceutical company) must be submitted to the local drug regulatory authority
Description Source: Wikipedia

[@shavnamchaudhary5034]

Appreciable work mam

[@DrShikhaParmarClasses]

Thank you for liking and appreciating the video 🙂

[@sjarun8641]

Thk u so much mam🙏

[@DrShikhaParmarClasses]

Thanks for watching and liking the video 🙂

[@hasnattariq2082]

madam plz cover chemotherapy section

[@Saikrupaatraders]

Are hindi mai bols kro yr

[@26693]

U go n learn english bastard😅😅